MA24342A1 - Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification - Google Patents

Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification

Info

Publication number
MA24342A1
MA24342A1 MA24398A MA24398A MA24342A1 MA 24342 A1 MA24342 A1 MA 24342A1 MA 24398 A MA24398 A MA 24398A MA 24398 A MA24398 A MA 24398A MA 24342 A1 MA24342 A1 MA 24342A1
Authority
MA
Morocco
Prior art keywords
modification
cdch
crystal
preparation
novel
Prior art date
Application number
MA24398A
Other languages
English (en)
French (fr)
Inventor
Grunenberg Alfous
Bosche Apotheker Patrick
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA24342(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of MA24342A1 publication Critical patent/MA24342A1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA24398A 1995-12-12 1996-11-22 Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification MA24342A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (1)

Publication Number Publication Date
MA24342A1 true MA24342A1 (fr) 1998-07-01

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
MA24398A MA24342A1 (fr) 1995-12-12 1996-11-22 Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification

Country Status (42)

Country Link
US (1) US5849752A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0780390B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP4104687B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100525146B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1061348C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR005009A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE221531T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU708006B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62258B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR9605968A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2192418C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO4480105A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CU (1) CU22774A3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ288657B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE19546249A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0780390T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE03474B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2179910T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP960558B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HU226521B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ID (1) ID22625A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL119795A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA24342A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY117492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL300109I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO306725B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ299905A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL184885B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT780390E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RO (1) RO119782B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2162468C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SA (1) SA96170492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG47201A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI0780390T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK282805B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SV (1) SV1996000109A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TR (1) TR199600970A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TW411340B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA35638C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
YU (1) YU49485B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA9610405B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1895233A (zh) * 1997-09-25 2007-01-17 拜尔公司 控释活性化合物的药物制剂
DE19751948A1 (de) 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
DK1128831T3 (da) 1998-11-10 2005-01-17 Bayer Healthcare Ag Farmaceutisk moxifloxacinpræparat
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) * 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
EP1562942A1 (en) * 2002-10-31 2005-08-17 Ranbaxy Laboratories, Ltd. Amorphous moxifloxacin hydrochloride
EP2113505A1 (en) 2003-04-09 2009-11-04 Dr. Reddy's Laboratories, Ltd. A crystalline form III of anhydrous moxifloxacin hydrochloride and processes for the preparation thereof
EP1651630A1 (en) * 2003-08-05 2006-05-03 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
WO2005054240A1 (en) * 2003-11-20 2005-06-16 Chemi Spa Polymorphs of 1-cyclopropyl-7-([s,s]-2,8-diazadicyclo[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride and methods for the preparation thereof
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
CN101484411A (zh) 2006-06-27 2009-07-15 桑多斯股份公司 盐的新制备方法
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
JP2010509305A (ja) * 2006-11-13 2010-03-25 シプラ・リミテッド モキシフロキサシン塩酸塩の合成方法
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
EP2349220B1 (en) 2008-10-09 2012-07-25 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Using of organic solvents in wet granulation of moxifloxacin
WO2010052726A1 (en) * 2008-11-06 2010-05-14 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
ES2467105T5 (es) 2008-12-08 2017-12-05 Ratiopharm Gmbh Moxifloxacino compactado
WO2010131054A1 (en) 2009-05-15 2010-11-18 Bradford Pharma Limited Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
EP2928892B1 (en) 2012-12-04 2018-03-21 Mankind Pharma Ltd. An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
AU2014239965A1 (en) 2013-03-15 2015-09-24 Melinta Subsidiary Corp. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
DK164287A (da) * 1986-03-31 1987-10-01 Sankyo Co Quinolin-3-carboxylsyrederivater og fremgangsmaade til fremstilling deraf og deres anvendelse
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1992-01-10 1993-07-21 Bayer Ag
CA2128601C (en) * 1992-01-31 2003-07-15 Hiroyuki Nagano Quinolone carboxylic acid derivatives in crystalline hydrate form
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
JP3268098B2 (ja) * 1992-12-25 2002-03-25 第一製薬株式会社 二環性環状アミン誘導体
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
EP0676199B1 (en) * 1994-04-07 1998-09-02 Pfizer Inc. Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections

Also Published As

Publication number Publication date
IL119795A0 (en) 1997-03-18
TR199600970A2 (tr) 1997-06-21
JP4104687B2 (ja) 2008-06-18
IN185805B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2001-05-05
SA96170492B1 (ar) 2006-05-23
US5849752A (en) 1998-12-15
RO119782B1 (ro) 2005-03-30
JPH09169757A (ja) 1997-06-30
EP0780390B1 (de) 2002-07-31
RU2162468C2 (ru) 2001-01-27
SG47201A1 (en) 1998-03-20
HRP960558A2 (en) 1998-02-28
DE59609501D1 (de) 2002-09-05
SI0780390T1 (en) 2002-10-31
BG62258B1 (bg) 1999-06-30
CA2192418A1 (en) 1997-06-13
AR005009A1 (es) 1999-04-07
HRP960558B1 (en) 2002-04-30
ID22625A (id) 1999-12-02
CZ288657B6 (cs) 2001-08-15
EE03474B1 (et) 2001-08-15
DK0780390T3 (da) 2002-11-11
EP0780390A1 (de) 1997-06-25
SV1996000109A (es) 1997-10-23
NL300109I1 (nl) 2003-02-03
PT780390E (pt) 2002-11-29
PL184885B1 (pl) 2003-01-31
BG101043A (en) 1998-04-30
BR9605968A (pt) 1998-08-18
CN1061348C (zh) 2001-01-31
EE9600201A (et) 1997-06-16
DE19546249A1 (de) 1997-06-19
NZ299905A (en) 1998-09-24
NO306725B1 (no) 1999-12-13
ZA9610405B (en) 1997-06-23
AU7421696A (en) 1997-06-19
ES2179910T3 (es) 2003-02-01
MY117492A (en) 2004-07-31
HUP9603428A2 (en) 1997-08-28
MX9606325A (es) 1997-10-31
HUP9603428A3 (en) 1997-10-28
YU65096A (sh) 1998-12-23
IL119795A (en) 1998-12-27
NO965298D0 (no) 1996-12-11
ATE221531T1 (de) 2002-08-15
HU9603428D0 (en) 1997-01-28
CU22774A3 (es) 2002-07-24
CN1160052A (zh) 1997-09-24
UA35638C2 (uk) 2001-04-16
AU708006B2 (en) 1999-07-29
HU226521B1 (en) 2009-03-30
KR970042550A (ko) 1997-07-24
KR100525146B1 (ko) 2006-01-27
TW411340B (en) 2000-11-11
CA2192418C (en) 2001-06-12
CZ364696A3 (en) 1997-07-16
SK159196A3 (en) 1997-10-08
SK282805B6 (sk) 2002-12-03
CO4480105A1 (es) 1997-07-09
YU49485B (sh) 2006-08-17
PL317415A1 (en) 1997-06-23
NO965298L (no) 1997-06-13

Similar Documents

Publication Publication Date Title
MA24342A1 (fr) Nouvelle modification du cristal de cdch, procede pour sa preparation et formules pharmaceutiques comprenant cette modification
MA23942A1 (fr) Formulation nouvelle contenant de la paroxetine, et procede pour sa preparation
EP0888053A4 (en) METHOD FOR TREATING CANCER AND INFECTIOUS DISEASES AND COMPOSITIONS THAT CAN BE USED THEREFOR
FI942076L (fi) Sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkaaineina
HUP9801836A2 (hu) Guaninszármazékok és eljárás ezek előállítására
FI942075A7 (fi) Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
FR2742148B1 (fr) Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
FI942077L (fi) Monomeerisiä sappihappojohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina
NO963499L (no) Hydroksaminsyre- og karboksylsyrederivater, fremgangsmåte for deres fremstilling og anvendelse derav
IS1665B (is) Nýjar króman og thíókróman afleiður
FR2722210B1 (fr) Nouvelles streptogramines et procede de preparation de streptogramines par mutasynthese
EP0761718A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
MA23412A1 (fr) Procede pour preparation de glycosides steroidiens , utiles comme agents hypocholesterolemiques et agents anti atherosclereux
FR2534139B1 (fr) Nouvelle forme galenique du sulpiride, son procede de preparation et medicament comprenant cette nouvelle forme
NO961797D0 (no) Anvendelse av benzopyranderivater for fremstilling av farmasöytiske sammensetninger beregnet for behandling av patologier forbundet med den Na+-uavhengige C1-HCO3-utbytter
EP0761721A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
MA26522A1 (fr) Composition pharmaceutique pour le traitement du diabete sucre et d'etats associes.
TNSN99124A1 (fr) Compositions pharmaceutiques mixtes pour le traitement de la faiblesse musculosquelettique et procede pour leur preparation.
EP0761719A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
FR2628421B1 (fr) Procede de preparation des derives de 1,4-dihydropyridine et nouveaux intermediaires utiles pour cette preparation
MA23953A1 (fr) Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites
BR9501921A (pt) Composto processo para sua preparação medicamento uso e método para inibir a atividade biológica do leucotrieno
EP0761720A3 (de) Herstellung von Poly-o-hydroxyamiden und Poly-o-mercaptoamiden
DK0808306T3 (da) Hidtil ukendte pyridin- eller pyridazinderivater, fremgangsmåder til fremstilling deraf og lægemidler indeholdende disse fo
ATE170527T1 (de) Phosphonobernsteinsäurederivate und ihre verwendung als arzneimittel